RU2394581C2 - ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ - Google Patents

ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ Download PDF

Info

Publication number
RU2394581C2
RU2394581C2 RU2007132181/15A RU2007132181A RU2394581C2 RU 2394581 C2 RU2394581 C2 RU 2394581C2 RU 2007132181/15 A RU2007132181/15 A RU 2007132181/15A RU 2007132181 A RU2007132181 A RU 2007132181A RU 2394581 C2 RU2394581 C2 RU 2394581C2
Authority
RU
Russia
Prior art keywords
day
ftd
dose
drug
days
Prior art date
Application number
RU2007132181/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2007132181A (ru
Inventor
Томохиро ЕМУРА (JP)
Томохиро ЕМУРА
Акира МИТА (JP)
Акира МИТА
Original Assignee
Тайхо Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2394581(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Тайхо Фармасьютикал Ко., Лтд. filed Critical Тайхо Фармасьютикал Ко., Лтд.
Publication of RU2007132181A publication Critical patent/RU2007132181A/ru
Application granted granted Critical
Publication of RU2394581C2 publication Critical patent/RU2394581C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2007132181/15A 2005-01-26 2006-01-25 ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ RU2394581C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US11/042,059 2005-01-26
JP2005165156 2005-06-06
JP2005-165156 2005-06-06

Publications (2)

Publication Number Publication Date
RU2007132181A RU2007132181A (ru) 2009-03-10
RU2394581C2 true RU2394581C2 (ru) 2010-07-20

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007132181/15A RU2394581C2 (ru) 2005-01-26 2006-01-25 ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ

Country Status (21)

Country Link
EP (1) EP1849470B2 (OSRAM)
JP (1) JP5576591B2 (OSRAM)
KR (1) KR101468216B1 (OSRAM)
AU (1) AU2006209547C1 (OSRAM)
BE (1) BE2017C028I2 (OSRAM)
CA (1) CA2594713A1 (OSRAM)
CY (2) CY2017029I2 (OSRAM)
DK (1) DK1849470T4 (OSRAM)
ES (1) ES2630002T5 (OSRAM)
FI (1) FI1849470T4 (OSRAM)
FR (1) FR17C1028I2 (OSRAM)
HU (2) HUE033306T2 (OSRAM)
LT (2) LT1849470T (OSRAM)
LU (1) LUC00036I2 (OSRAM)
NL (1) NL300889I2 (OSRAM)
PL (1) PL1849470T5 (OSRAM)
PT (1) PT1849470T (OSRAM)
RU (1) RU2394581C2 (OSRAM)
SI (1) SI1849470T2 (OSRAM)
TW (1) TWI362265B (OSRAM)
WO (1) WO2006080327A1 (OSRAM)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340808B2 (en) 2012-03-14 2016-05-17 Nisshin Pharma Inc. Sulfur amino acid-containing composition
RU2585528C2 (ru) * 2011-08-16 2016-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
RU2639473C2 (ru) * 2012-02-15 2017-12-21 Тайхо Фармасьютикал Ко., Лтд. Пероральная фармацевтическая композиция
RU2727598C2 (ru) * 2016-02-05 2020-07-22 Тайхо Фармасьютикал Ко., Лтд. Способ лечения больных раком с тяжелой почечной недостаточностью

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
PT1849470T (pt) 2005-01-26 2017-09-22 Taiho Pharmaceutical Co Ltd Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8536188B2 (en) 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
CN102014877B (zh) 2008-01-25 2017-06-06 格吕伦塔尔有限公司 药物剂型
PL2273983T3 (pl) 2008-05-09 2017-01-31 Grünenthal GmbH Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
JP2011520845A (ja) * 2008-05-15 2011-07-21 カソリック ユニヴェルシテイト ルーヴェン，ケー．ユー． ルーヴェン アール アンド ディー 抗癌剤の組合せによる治療
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
MX348491B (es) 2011-07-29 2017-06-15 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR20150009540A (ko) 2012-05-16 2015-01-26 노파르티스 아게 Pi-3 키나제 억제제에 대한 투여 요법
HUE041687T2 (hu) * 2013-03-27 2019-05-28 Taiho Pharmaceutical Co Ltd Antitumor szer, amely tartalmaz kis dózisú irinotekan-hidroklorid-hidrát-ot
JP5976923B2 (ja) * 2013-03-27 2016-08-24 大鵬薬品工業株式会社 イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JP6312660B2 (ja) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
RS64243B1 (sr) 2013-09-06 2023-06-30 Taiho Pharmaceutical Co Ltd Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
JP6871868B2 (ja) * 2016-01-08 2021-05-19 大鵬薬品工業株式会社 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
WO2026019875A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227726B1 (en) * 1995-03-29 2012-01-30 Taiho Pharmaceutical Co Ltd Uracyl-derivatives and antitumor effect potentiator and antitumor agent containing the same
DK0884051T3 (da) * 1996-09-24 2005-01-24 Taiho Pharmaceutical Co Ltd Cancröse metastaseinhibitorer indeholdende uracilderivater
PT1849470T (pt) 2005-01-26 2017-09-22 Taiho Pharmaceutical Co Ltd Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Tomohiro Emura et al. International Journal of Molecular Medicine. Vol.13, №2, 2004, pp.249-255. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2585528C2 (ru) * 2011-08-16 2016-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
US9371380B2 (en) 2011-08-16 2016-06-21 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer
RU2639473C2 (ru) * 2012-02-15 2017-12-21 Тайхо Фармасьютикал Ко., Лтд. Пероральная фармацевтическая композиция
US9340808B2 (en) 2012-03-14 2016-05-17 Nisshin Pharma Inc. Sulfur amino acid-containing composition
RU2727598C2 (ru) * 2016-02-05 2020-07-22 Тайхо Фармасьютикал Ко., Лтд. Способ лечения больных раком с тяжелой почечной недостаточностью
US10960004B2 (en) 2016-02-05 2021-03-30 Taiho Pharmaceutical Co., Ltd. Method for treating cancer patients with severe renal impairment

Also Published As

Publication number Publication date
HUE033306T2 (hu) 2017-11-28
FR17C1028I2 (fr) 2018-11-02
TW200637562A (en) 2006-11-01
WO2006080327A1 (ja) 2006-08-03
KR20070104559A (ko) 2007-10-26
FR17C1028I1 (OSRAM) 2017-09-29
CY1119393T1 (el) 2018-02-14
NL300889I1 (nl) 2017-08-14
JPWO2006080327A1 (ja) 2008-06-19
LUC00036I2 (OSRAM) 2017-12-01
HUS1700032I1 (hu) 2017-09-28
CA2594713A1 (en) 2006-08-03
BE2017C028I2 (OSRAM) 2025-09-10
PT1849470T (pt) 2017-09-22
KR101468216B1 (ko) 2014-12-03
ES2630002T3 (es) 2017-08-17
TWI362265B (en) 2012-04-21
DK1849470T3 (en) 2017-08-14
PL1849470T3 (pl) 2017-11-30
SI1849470T2 (sl) 2024-05-31
NL300889I2 (nl) 2018-01-16
LT1849470T (lt) 2017-07-25
PL1849470T5 (pl) 2024-06-10
CY2017029I1 (el) 2018-02-14
LTC1849470I2 (lt) 2019-10-25
AU2006209547A1 (en) 2006-08-03
LTPA2017024I1 (lt) 2017-08-10
EP1849470A1 (en) 2007-10-31
EP1849470A4 (en) 2010-12-08
JP5576591B2 (ja) 2014-08-20
EP1849470B2 (en) 2024-03-20
CY2017029I2 (el) 2018-02-14
FI1849470T4 (fi) 2024-03-22
AU2006209547C1 (en) 2022-04-07
LUC00036I1 (OSRAM) 2017-10-02
SI1849470T1 (sl) 2017-10-30
DK1849470T4 (en) 2024-04-02
AU2006209547B2 (en) 2011-05-26
RU2007132181A (ru) 2009-03-10
ES2630002T5 (es) 2024-09-19
EP1849470B1 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
RU2394581C2 (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US20120157472A1 (en) Method for treating colorectal cancer
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
JP2016014051A (ja) ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置
CN113893256A (zh) 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
KR100740079B1 (ko) 당뇨병성 신경 장해용 의약 조성물
US20240122921A1 (en) Methods for cancer therapy
HK40059774A (en) Application of compound or pharmaceutically acceptable salt, dimer or trimer thereof in the preparation of medicament for treating cancer
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
TW200846013A (en) Cytidine derivative-containing antitumor agent for continuous intravenous administration
CN109152761A (zh) 使用吲唑基苯甲酰胺衍生物治疗癌症的组合疗法
JP2003300888A (ja) 抗腫瘍効果増強剤